Enanta Pharmaceuticals | ENTA - Equity Capital And Reserves


Enanta Pharmaceuticals reported $126.59M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Immunic USD 10.5M 23.41M Sep/2025
Incyte USD 5.17B 516.28M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
J&J USD 78.47B 0 Sep/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 44.75B 2.7B Sep/2025
Novavax USD -156.67M 194.3M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025